Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Graves' Ophthalmopathy (GRC)
NCT01297699Phase 3Completed
- Sponsor
- Complejo Hospitalario Universitario de Santiago
- Start
- Mar 2012
- Primary completion
- Oct 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in Graves' ophthalmopathy (TED), sponsored by Complejo Hospitalario Universitario de Santiago. Started Mar 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT01297699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297699.